Document Detail


Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.
MedLine Citation:
PMID:  1715268     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Celiprolol is a hydrophilic, beta 1-selective adrenoceptor antagonist with mild selective beta 2-agonist as well as weak vasodilator properties. Celiprolol 200 to 400mg once daily by mouth is similar in antihypertensive efficacy to usual doses of propranolol, atenolol, metoprolol and pindolol in patients with mild to moderate systemic hypertension. Similar doses of celiprolol are as efficacious as propranolol and atenolol in improving exercise tolerance and reducing the frequency of anginal attacks in patients with angina pectoris. Further clinical experience suggests that celiprolol does not produce bronchoconstriction and may have mild bronchodilating activity in asthmatic patients; it may also enhance the effects of bronchodilator drugs. Celiprolol has a slightly beneficial effect on serum lipid profiles, and does not appear to exert adverse effects on carbohydrate metabolism. If the apparent pharmacodynamic advantages of celiprolol translate into clinical benefits and are confirmed in well designed long term clinical trials, then celiprolol should represent a definite advance in beta-blocker therapy.
Authors:
R J Milne; M M Buckley
Related Documents :
2888298 - Electrophysiologic effects of beta blockers in ventricular arrhythmias.
823568 - Pentylenetetrazol-induced amnesia: a case for overt seizures.
20100598 - Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protei...
1352618 - The vasa vasorum and the paradox of beta-blocker therapy.
21148128 - Lost in translation: neuropsychiatric drug development.
10234538 - Modified water containing hydrophilic ointment with suspended hydrocortisone-21-acetate...
Publication Detail:
Type:  Clinical Trial; Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  41     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1991 Jun 
Date Detail:
Created Date:  1991-10-03     Completed Date:  1991-10-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  941-69     Citation Subset:  IM    
Affiliation:
Adis Drug Information Services, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists* / therapeutic use
Angina Pectoris / drug therapy*
Animals
Antihypertensive Agents* / therapeutic use
Celiprolol
Dogs
Hemodynamics / drug effects
Humans
Hypertension / drug therapy*
Lipids / blood
Propanolamines* / administration & dosage,  pharmacokinetics,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Lipids; 0/Propanolamines; 56980-93-9/Celiprolol
Comments/Corrections
Erratum In:
Drugs 1991 Oct;42(4):639
Drugs 1992 Feb;43(2):145

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhiniti...
Next Document:  Characterization of the adrenal 11 beta-hydroxylase in inbred salt-sensitive and resistant rats.